QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

Summary

This study will evaluate the safety, tolerability, and mechanism of action of multiple doses of QAX576 in patients with pulmonary fibrosis secondary to systemic sclerosis

Timeline

Start

2007-12

Primary completion

2009-04

Completion

—

Drugs

Indications